Senescent glia sustain neuronal choline homeostasis via SASP‑mediated phospholipid release—a metabolic chaperone role that senolytics may inadvertently impair

Hypothesis

Senescent astrocytes and microglia actively supply choline‑derived phospholipids to neighboring neurons through the secretion of SASP‑enriched extracellular vesicles (EVs). This cholinergic support maintains membrane integrity and acetylcholine synthesis during aging, acting as a metabolic chaperone. Consequently, broad senolytic clearance reduces neuronal choline availability, potentially offsetting anti‑inflammatory benefits under conditions where membrane repair is critical.

Mechanistic Reasoning

1. Senescent glial SASP includes phosphatidylcholine‑rich EVs – Recent work shows that senescent fibroblasts release EVs loaded with phospholipids that can be taken up by target cells (SASP EVs and lipid transport). We hypothesize a similar phenotype in brain‑resident senescent glia, driven by upregulated choline kinase (CHKA) and CTP:phosphocholine cytidylyltransferase (PCYT1A) as part of a compensatory secretory program.
2. Neuronal dependence on glial choline supply – Age‑related decline in blood‑brain barrier choline transport (16 % vs 60 % uptake) creates a reliance on locally sourced choline for CDP‑choline synthesis and acetylcholine production (acetylcholine falls with senescence). Senescent glia could alleviate this deficit by exporting choline metabolites.
3. SASP‑mediated one‑carbon flux modulation – Senescent cells exhibit altered folate metabolism (one‑carbon pathway in senescence). Increased EVs carrying betaine or dimethylglycine could support neuronal methylation cycles, indirectly stabilizing choline homeostasis.

Testable Predictions

• Prediction 1: Isolated EVs from senescent astrocytes (induced by irradiation or oncogenic RAS) will contain higher phosphatidylcholine and choline‑phosphate levels than EVs from non‑senescent controls (quantified by LC‑MS).
• Prediction 2: Co‑culture of neurons with senescent glial EVs will rescue neuronal choline uptake and CDP‑choline synthesis under low‑extracellular choline conditions, measured with radiolabeled [^3H]‑choline.
• Prediction 3: In vivo, acute senolytic treatment (dasatinib + quercetin) in aged mice will reduce extracellular choline‑phosphate levels in the hippocampal interstitial fluid (microdialysis) and decrease neuronal phosphatidylcholine synthesis (^13C‑choline tracing).
• Prediction 4: The cognitive benefits of senolytics will be attenuated or reversed when choline supplementation is withdrawn, revealing a conditional dependence on glial‑derived choline.

Experimental Approach (brief)

1. Generate senescent astrocytes via low‑dose ethanol exposure; isolate EVs; perform lipidomics.
2. Treat primary hippocampal neurons with choline‑deficient medium ± senescent glial EVs; assess choline uptake, CDP‑choline flux (using ^14C‑choline), and acetylcholine release.
3. Aged C57BL/6 mice receive senolytics or vehicle for 4 weeks; administer oral ^13C‑choline; collect brain microdialysate and measure labeled phosphatidylcholine via mass spectrometry.
4. Parallel cohorts receive choline supplementation (CDP‑choline 300 mg/kg) to test rescue of any senolytic‑induced memory deficits in the Morris water maze.

Falsifiability

If senescent glial EVs do not show enriched choline phospholipids, or if neuronal choline metrics remain unchanged after senolytic clearance, the hypothesis is refuted. Likewise, if choline supplementation fails to modulate the cognitive outcomes of senolytics, the proposed metabolic chaperone role lacks physiological relevance.

Implications

This work reframes senescent glia not merely as inflammatory sources but as potential nutrient niches. It suggests that senolytic strategies may need compartmentalization—targeting deleterious SASP components while preserving beneficial lipid EVs—or be paired with choline‑based supplements to sustain neuronal membrane homeostasis in aging brains.